These leases comprise 33632 acres in totalapproximately 15% of the entire P

These leases comprise 33,632 acres in total,approximately 15% of the entire P.R Spring deposit It is estimated theP.R. The Cohen Financial and Valuation Model, an analytical andportfolio management system, is a 100+ page income statement model withseven (7) equity valuation and three (3) cash flow analytical models Ourmodel covers 9,000 public companies. For more information, readers canvisit the company’s website at Cobra Oil & Gas Co.Cobra Oil & Gas Co. is a publicly traded independent oil and gasexploration and production company headquartered in Houston, Texas(OTCBB: CGCA) Cobra Oil & Gas signed an LOI with Enercor Inc.

for thepurchase of a 20% lease assignment upon completion of financingactivities on 23 Federal Leases in the central region of the P.R. The backboneof the fundamental research targeted at stock investment includesinvestigative research into significant corporate events, thorough reviewof SEC filings, in depth financial analysis, valuations, and managementprofiles. Mr.Cohen was also the West Coast Senior Vice President of CBWL-HaydenStone-American Express Mr Cohen’s partners were Sanford I. Weill (pastChairman and CEO of CitiGroup and past Chairman of Solomon Smith Barney)and Arthur Levitt (past Chairman of the Securities and Exchange Commission(SEC)).Cohen Independent Research Group includes nine PhDs (three with MDs), twoMDs, six CFAs (chartered financial analyst), three with CPAs (certifiedpublic accountant) and 21 analysts covering most industries. As founder of Bear Stearns Western RegionalOffices, Paul Cohen was one of the original 12 Dirty Dozen analysts,regarded by many to be the top 12 security analysts in the nation.

HOUSTON, TX, Jul 20 (MARKET WIRE) — Cobra Oil & Gas Company (OTCBB: CGCA) (hereafter “Cobra”) — A newresearch report has been issued on Cobra Oil & Gas Co. by CohenIndependent Research Group, Wall Street’s leading independent researchfirm, with a “BUY” recommendation and a $3.65 long-term price target.For the full report please visit Cobra’s website at ,or Cohen Independent Research Group’s website, Cohen Independent Research Group:Led by Paul Cohen, Cohen Independent Research Group is Wall Street’s #1Independent Research Firm. Idenix anticipates that subsequent events and developments maycause these views, expectations and beliefs to change. However, while Idenixmay elect to update these forward-looking statements at some point in thefuture, it specifically disclaims any obligation to do so.SOURCEIdenix Pharmaceuticals, Inc.Media: Teri Dahlman, +1-617-995-9905, or Investors: Amy Sullivan,+1-617-995-9838, both of Idenix Pharmaceuticals. All forward-looking statements reflect the company’s expectations only as ofthe date of this release and should not be relied upon as reflecting thecompany’s views, expectations or beliefs at any date subsequent to the date ofthis release. ET.To accessthe replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 Internationaland enter passcode 20088902.

An archived webcast will also be available fortwo weeks after the call on the Idenix website.About IdenixIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is abiopharmaceutical company engaged in the discovery and development of drugsfor the treatment of human viral diseases. Idenix’s current focus is on thetreatment of infections caused by hepatitis C virus. For further informationabout Idenix, please refer to StatementsThis press release contains “forward-looking statements” within the meaning ofThe Private Securities Litigation Reform Act of 1995. Such forward-lookingstatements can be identified by the use of forward-looking terminology such as”expect,” “plans,” “anticipates,” “will,” “expects,” “goal” or similarexpressions, or by express or implied statements with respect to the company’sclinical development programs or commercialization activities in hepatitis C,or any potential pipeline candidates, including any expressed or impliedstatements regarding the efficacy and safety of IDX184, the likelihood andsuccess of any future clinical trials involving IDX184 or successfuldevelopment of novel combinations of direct-acting antivirals for thetreatment of hepatitis C. These and other risks which may impactmanagement’s expectations are described in greater detail under the caption”Risk Factors” in the company’s annual report on Form 10-K for the year endedDecember 31, 2008 and the Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2009, as filed with the Securities and Exchange Commission (SEC) andother filings that the company makes with the SEC.

There can be noguarantees that the company will advance any clinical product candidate orother component of its potential pipeline to the clinic, to the regulatoryprocess or to commercialization. Such forward-looking statements involve known andunknown risks, uncertainties and other factors that may cause actual resultsto be materially different from any future results, performance orachievements expressed or implied by such statements. Conference Call InformationIdenix will hold a conference call and webcast today at 4:30 p.m. ET.Toaccess the call please dial 800-774-5358 U.S./Canada or 706-758-9475International and enter passcode 20088902 or to listen to a live webcast andview accompanying slides, go to “Calendar of Events” in the Idenix InvestorCenter at replay of the call will also be available from6:30 p.m ET on July 20, 2009 until August 3, 2009 12:00 a.m. Thistechnology enables the delivery of nucleoside monophosphate to the liver,leading to the formation of high levels of nucleoside triphosphate,potentially maximizing drug efficacy and limiting systemic side effects withlow, once-daily dosing of drug. “With the successful completion of the proof-of-conceptstudy for IDX184 and plans to file investigational new drug applications inthe coming months from our non-nucleoside polymerase inhibitor and proteaseinhibitor programs, we are closer to achieving our ultimate goal of developingnovel combinations of direct-acting antivirals for the treatment of hepatitisC.”The company plans to report the full data set from this study at a scientificmeeting later this year.About IDX184IDX184 is a novel, liver-targeted 2′-methyl guanosine nucleotide prodrug,which includes Idenix’s proprietary liver-targeting technology.